Tags : METEOR trial


Ipsen’s Cabometyx Receives Health Canada’s Approval for the Treatment of

Shots: Approval of Cabometyx (cabozantinib) is based on results of the P-III METEOR trial assessing Cabometyx vs everolimus for advanced (RCC) previously received vascular endothelial growth factor (VEGF) targeted therapy, demonstrated significant and clinical improvement in OR, PFS, ORR Cabometyx received priority review status from Health Canada further assisted its approval. In 2017, the US […]Read More